AbbVie stock sits 3.06 percent below its 52-week high
Published on 10/14/2026 at 11:45 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSUpcoming dates shape the test
- AbbVie reported USD 16.99 billion in second-quarter 2026 revenue, up 10.20 percent year over year.
- MarketBeat puts consensus third-quarter 2026 revenue at USD 17.34 billion on October 30, 2026.
- AbbVie stock trades at EUR 245.55 at 11:41 a.m. CEST at Lang & Schwarz on October 14, 2026, 0.83 percent below the Xetra close of October 13, 2026.
AbbVie Inc. (ISIN US00287Y1091) was trading at EUR 245.55 at Lang & Schwarz on October 14, 2026 at 11:41 a.m. CEST, 3.06 percent below its 52-week high of EUR 253.30. On October 1, 2026, AbbVie announced that it would publish third-quarter results on October 30, 2026, before the market opens, as Trivano reported.
Stock remains below yearly high
The EUR 7.75 gap to the 52-week high places the current Lang & Schwarz quote 3.06 percent below that level. The comparison matters because the stock is also approaching a scheduled earnings event, while the latest available quarterly figures provide a measurable baseline.
Revenue sets a higher bar
AbbVie reported USD 16.99 billion in revenue for the second quarter of 2026, up 10.20 percent year over year, according to MarketBeat. The same report lists adjusted earnings per share of USD 3.65 against a USD 3.61 consensus, a USD 0.04 beat for the second quarter.
For the third quarter of 2026, MarketBeat lists consensus revenue of USD 17.34 billion and consensus earnings per share of USD 3.80. That forecast gives the October report a higher revenue bar than the USD 16.99 billion recorded in the second quarter.
What does the next report add?
The answer will come through the October 30, 2026 release, scheduled before the market opens, followed by a conference call at 9:00 a.m. ET, according to MarketBeat. The USD 17.34 billion revenue estimate and USD 3.80 earnings-per-share estimate are the clearest numerical tests for the next update.
Three dated milestones
On July 31, 2026, AbbVie reported second-quarter revenue of USD 16.99 billion and adjusted earnings per share of USD 3.65, according to MarketBeat. On October 1, 2026, the company set October 30, 2026 for its third-quarter results, while on October 7, 2026, Morgan Stanley raised its target from USD 296.00 to USD 310.00 and kept an overweight rating, as Transcript Daily reported.
Dates and payout provide context
AbbVie has an ex-dividend date of October 15, 2026, with a quarterly dividend of USD 1.73 per share, according to Transcript Daily. The next earnings release follows on October 30, 2026, giving the dividend date and the results date separate near-term reference points.
Price stays below the annual peak
At Lang & Schwarz, AbbVie stock was trading at EUR 245.55 on October 14, 2026 at 11:41 a.m. CEST, down EUR 2.05, or 0.83 percent, versus the Xetra close of October 13, 2026 at EUR 247.60. The further course of trading is shown by the continuously updated real-time quote of AbbVie stock.
AbbVie stock facts
- Company: AbbVie Inc.
- ISIN: US00287Y1091
- Ticker: ABBV
- Primary exchange: NYSE
- Price Lang & Schwarz (as of October 14, 2026, 11:41 a.m. CEST): EUR 245.55
- Change versus Xetra close: minus 0.83 percent
- Xetra close (October 13, 2026): EUR 247.60
- Market capitalization: EUR 434.6 billion (as of October 14, 2026)
- 52-week range: EUR 162.85-253.30 (as of October 14, 2026)
- Sector / Industry: Healthcare / Drug Manufacturers - General
- Next earnings date: October 30, 2026
Market context: Market report S&P 500.
